top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
816_aicvd (8)_9_edited.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
f055739f-1956-41a1-8156-cda95d1fea9f.png
AI-CVD Bundle
Muscle and Fat Analysis.png
Liver Attenuation.png
Cardiac Chambers Volumetry.png
ٍEpicardial Fat .png
Bone Mineral Density (BMD) .png
coronaryArteryCalcification.png
Lung Density Report- High Attenuation Index.png
Thoracic Aorta and Pulmonary Artery Sizing .png
Aortic Wall Aortic and Mitral Valve Report.png
Lung Density Report- Low Attenuation Index.png
AI-CVD--.png
Frame 1000008286.png
Frame 1000008286.png
Frame 1000008287.png

Performance of Sybil AI for lung cancer risk assessment: a head-to-head comparison of cardiac vs. lung CT scans

Aug 17
1 min read

ESC Congress 2026 - 28 - 31 Aug 2026

Munich, Germany

Organised by: European Society of Cardiology (ESC) visual



Can AI assess lung cancer risk from a cardiac CT—even when the entire lung isn’t visible?

In this study, Sybil AI was evaluated head-to-head on cardiac coronary artery calcium (CAC) scans and full chest CT scans across 4,486 scans from the FHS and MESA cohorts.


Despite the limited lung field of view, Sybil maintained strong lung cancer risk prediction on cardiac CT, with AUC remaining above 0.80 through 6 years.


These findings highlight an important opportunity: using existing CAC scans acquired for cardiovascular prevention to provide additional insight into lung cancer risk—without requiring an additional scan.


Download the full presentation below to explore the study, results, and clinical implications.



Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page